Tocilizumab treatment in COVID-19: A single center experience

Journal of Medical Virology

Volumn 92, Issue 7, 2020, Pages 814-818

  Luo, Pan ^a   Liu, Yi ^a   Qiu, Lin ^a   Liu, Xiulan ^a   Liu, Dong ^a   Li, Juan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

COVID 19; cytokine storms; interleukin 6; SARS CoV 2; Tocilizumab

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; METHYLPREDNISOLONE; TOCILIZUMAB; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; CRITICALLY ILL PATIENT; CYTOKINE STORM; DEMOGRAPHY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HUMAN; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SINGLE DRUG DOSE; BETACORONAVIRUS; BLOOD; CHINA; COMBINATION DRUG THERAPY; CORONAVIRUS INFECTION; DRUG ADMINISTRATION; DRUG EFFECT; EPIDEMIC; EPIDEMIOLOGY; METABOLISM; MORTALITY; PANDEMIC; PATHOGENICITY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; VIRUS PNEUMONIA;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; BETACORONAVIRUS; BIOMARKERS; C-REACTIVE PROTEIN; CHINA; CORONAVIRUS INFECTIONS; DISEASE OUTBREAKS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-6; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PANDEMICS; PNEUMONIA, VIRAL; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85083217713     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.25801     Document Type: Article

References (8)

1. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420-422.
2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
4. Kaur S, Bansal Y, Kumar R, Bansal G. A panoramic review of IL-6: structure, pathophysiological roles and inhibitors. Bioorg Med Chem. 2020;28(5):115327.
5. Xu YH, Dong JH, An WM, et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J Infect. 2020;80:394-400.
6. Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15(8):813-822.
7. Chiaretti A, Pulitanò S, Barone G, et al. IL-1 beta and IL-6 upregulation in children with H1N1 influenza virus infection. Mediators Inflamm. 2013;2013:495848.
8. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959-3964.